<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Esperion Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/esperion-therapeutics-inc</link>
<description>Latest news and press releases for Esperion Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/esperion-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835647278dffbe2df0efab3.webp</url>
<title>Esperion Therapeutics Inc</title>
<link>https://6ix.com/company/esperion-therapeutics-inc</link>
</image>
<item>
<title>Esperion to Report First Quarter 2026 Financial Results on May 7</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/esperion-to-report-first-quarter-2026-financial-results-on-may-7</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/esperion-to-report-first-quarter-2026-financial-results-on-may-7</guid>
<pubDate>Thu, 23 Apr 2026 12:00:00 GMT</pubDate>
<description>ANN ARBOR, Mich., April 23, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours aft</description>
</item>
<item>
<title>Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/esperion-therapeutics-closes-acquisition-of-corstasis-therapeutics-expanding-its-cardiovascular-franchise-with-enbumysttm-bumetanide-nasal-spray</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/esperion-therapeutics-closes-acquisition-of-corstasis-therapeutics-expanding-its-cardiovascular-franchise-with-enbumysttm-bumetanide-nasal-spray</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>– Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion’s Cardiovascular Franchise, Anticipated to Drive Portfolio</description>
</item>
<item>
<title>Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/athyrium-capital-management-and-esperion-enter-into-dollar50-million-japan-royalty-financing-to-support-strategic-acquisition-of-corstasis-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/athyrium-capital-management-and-esperion-enter-into-dollar50-million-japan-royalty-financing-to-support-strategic-acquisition-of-corstasis-therapeutics</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Athyrium Funds purchased a portion of the royalties payable to Esperion on Japan net sales of Otsuka’s bempedoic acid products, together with related</description>
</item>
<item>
<title>Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/esperion-to-participate-in-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/esperion-to-participate-in-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>ANN ARBOR, Mich., March 31, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 25th</description>
</item>
<item>
<title>Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/esperion-showcases-new-data-from-clear-outcomes-highlighting-value-of-nexletolr-bempedoic-acid-at-the-american-college-of-cardiologys-annual-scientific-session-2026</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/esperion-showcases-new-data-from-clear-outcomes-highlighting-value-of-nexletolr-bempedoic-acid-at-the-american-college-of-cardiologys-annual-scientific-session-2026</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>– Analysis Demonstrated 22% Reduced Risk of Ischemic Stroke for Patients Taking Bempedoic Acid Compared to Placebo – – Analysis of CLEAR Outcomes Reports</description>
</item>
<item>
<title>Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/esperion-to-present-two-new-analyses-from-clear-outcomes-clinical-trial-at-the-american-college-of-cardiology-2026-annual-scientific-session</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/esperion-to-present-two-new-analyses-from-clear-outcomes-clinical-trial-at-the-american-college-of-cardiology-2026-annual-scientific-session</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>Reviews Bempedoic Acid as Therapeutic Option for Diverse Patient Populations in Need of Alternatives to Statins in Cardiovascular Risk Management ANN ARBOR,</description>
</item>
<item>
<title>Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/esperions-bempedoic-acid-receives-multiple-class-1-recommendations-in-2026-accaha-multisociety-guideline-for-management-of-dyslipidemia</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/esperions-bempedoic-acid-receives-multiple-class-1-recommendations-in-2026-accaha-multisociety-guideline-for-management-of-dyslipidemia</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary</description>
</item>
<item>
<title>Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/esperion-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/esperion-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew</description>
</item>
<item>
<title>/C O R R E C T I O N -- HLS Therapeutics Inc./</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/c-o-r-r-e-c-t-i-o-n-hls-therapeutics-inc</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/c-o-r-r-e-c-t-i-o-n-hls-therapeutics-inc</guid>
<pubDate>Thu, 05 Mar 2026 13:55:00 GMT</pubDate>
<description>HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, today announced the commercial launch of NILEMDO™ (bempedoic acid) in Canada. NILEMDO is now available by prescription nationally. HLS in-licensed the exclusive rights to NILEMDO and NEXLIZET® (bempedoic acid and ezetimibe) for the Canadian market from Esperion Therapeutics Inc. ("Esperion") (NASDAQ: ESPR) in M</description>
</item>
<item>
<title>Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/esperion-therapeutics-and-corstasis-therapeutics-announce-esperions-definitive-agreement-to-acquire-corstasis-expanding-its-cardiovascular-franchise-with-enbumysttm-bumetanide-nasal-spray</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/esperion-therapeutics-and-corstasis-therapeutics-announce-esperions-definitive-agreement-to-acquire-corstasis-expanding-its-cardiovascular-franchise-with-enbumysttm-bumetanide-nasal-spray</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>– Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion’s</description>
</item>
<item>
<title>Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/esperion-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-10</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/esperion-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-10</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2025 financial results</description>
</item>
<item>
<title>Esperion to Participate in The 2026 Citizens Life Sciences Conference</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/esperion-to-participate-in-the-2026-citizens-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/esperion-to-participate-in-the-2026-citizens-life-sciences-conference</guid>
<pubDate>Wed, 18 Feb 2026 05:00:00 GMT</pubDate>
<description>ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2026</description>
</item>
<item>
<title>Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/esperion-reaches-settlement-agreement-fifth-130000895</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/esperion-reaches-settlement-agreement-fifth-130000895</guid>
<pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
<description>ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion against Alkem in response to Alkem’s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Alkem has agreed not to market</description>
</item>
<item>
<title>Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/esperion-announces-inducement-grants-under-213000744</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/esperion-announces-inducement-grants-under-213000744</guid>
<pubDate>Wed, 11 Feb 2026 21:30:00 GMT</pubDate>
<description>ANN ARBOR, Mich., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on February 10, 2026, the Company granted 11 new employees 40,200 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement</description>
</item>
<item>
<title>Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/esperion-provides-business-44th-annual-230000908</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/esperion-provides-business-44th-annual-230000908</guid>
<pubDate>Sun, 11 Jan 2026 23:00:00 GMT</pubDate>
<description>– Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 – –Total Preliminary* Revenue of $400 to $408 million, a 20% to 23% Increase Compared With Full-Year 2024, and ~55% to 59% Increase Excluding One-Time Milestones – – Cash and Cash Equivalents of Approximately $168 Million* at Year-End 2025 – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Expects Operating Expenses of Between $210 Million an</description>
</item>
<item>
<title>Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/esperion-participate-upcoming-44th-annual-130000340</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/esperion-participate-upcoming-44th-annual-130000340</guid>
<pubDate>Mon, 05 Jan 2026 13:00:00 GMT</pubDate>
<description>ANN ARBOR, Mich., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at J.P. Morgan’s 44th Annual Healthcare Conference on Wednesday, January 14, 2025. The company’s presentation and participation in a fireside chat will begin at 2:15 p.m. PT/5:15 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the</description>
</item>
<item>
<title>Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/esperion-bempedoic-acid-receives-recommendation-130000795</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/esperion-bempedoic-acid-receives-recommendation-130000795</guid>
<pubDate>Fri, 19 Dec 2025 13:00:00 GMT</pubDate>
<description>– Bempedoic Acid Highlighted by ACC for LDL-C Lowering in Patients with Peripheral Artery Disease and Diabetes Based on Proven Cardiovascular and Limb Benefits – ANN ARBOR, Mich., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) welcomed the inclusion of bempedoic acid as a first-line, evidence-based therapy for LDL-C lowering for patients on maximally tolerated statins in the 2025 American College of Cardiology (ACC) Scientific Statement on Management of Peripheral Artery Disease (PAD)</description>
</item>
<item>
<title>Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/esperion-partner-otsuka-launches-nexletol-130000317</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/esperion-partner-otsuka-launches-nexletol-130000317</guid>
<pubDate>Fri, 21 Nov 2025 13:00:00 GMT</pubDate>
<description>– Company to Receive $90 Million Total Payment – – Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL – ANN ARBOR, Mich., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner in Japan for the development and commercialization of NEXLETOL® (bempedoic acid) tablets, received National Health Insurance Price Listing and launched NEXLETOL for t</description>
</item>
<item>
<title>Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/esperion-participate-piper-sandler-37th-130000507</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/esperion-participate-piper-sandler-37th-130000507</guid>
<pubDate>Wed, 19 Nov 2025 13:00:00 GMT</pubDate>
<description>ANN ARBOR, Mich., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025, at 3:30 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Espe</description>
</item>
<item>
<title>Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease</title>
<link>https://6ix.com/company/esperion-therapeutics-inc/news/esperion-partner-hls-therapeutics-announces-120000318</link>
<guid isPermaLink="true">https://6ix.com/company/esperion-therapeutics-inc/news/esperion-partner-hls-therapeutics-announces-120000318</guid>
<pubDate>Tue, 18 Nov 2025 12:00:00 GMT</pubDate>
<description>ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company’s partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for NILEMDO is expected in Q2 2026. “This approval marks a</description>
</item>
</channel>
</rss>